Key facts
- This page summarizes William E. Duke's Form 4 filing for Apexigen, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 May 2023, 16:21.
William E. Duke - 23 May 2023 Form 4 Insider Report for Apexigen, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 23 May 2023
- Net transaction value
- -$6,904
- SEC form
- 4
- Accepted by SEC
- 25 May 2023, 16:21:23 UTC
- Prior SEC filing
- 19 Dec 2022
- Next SEC filing
- 23 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francis Sarena, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William E. Duke filed Form 4 for Apexigen, Inc. on 25 May 2023.
Change
- Previous filing in this sequence was filed on 19 Dec 2022.
- Current net transaction value: -$6,904.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APGN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- +573%
- Price
- $0.000000
- Shares after
- 176,182
- Date
- 23 May 2023
- Ownership
- Direct
- Footnotes
- F1
APGN
transaction
Common Stock
Tax liability
- Transaction value
- $6,904
- Shares
- -17,261
- Change %
- -9.8%
- Price
- $0.4000
- Shares after
- 158,921
- Date
- 23 May 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported shares are represented by restricted stock units, or RSUs. Upon signing of the merger agreement between the Issuer and Pyxis Oncology, Inc. dated May 23, 2023, 60,000 RSUs vested. The remaining 90,000 RSUs vest on the earlier of (i) the closing of the merger or (ii) September 30, 2023.
Footnote F2
The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.